Ease-of-use preference for the ELLIPTA® dry powder inhaler over a commonly used single-dose capsule dry powder inhaler by inhalation device-naïve Japanese volunteers aged 40 years or older

International Journal of COPD

Volumn 9, Issue , 2014, Pages 1365-1375

  Komase, Yuko ^a   Asako, Akimoto ^b   Kobayashi, Akihiro ^b   Sharma, Raj ^c  

^a ST MARIANNA UNIVERSITY   (Japan)

^b Development and Medical Affairs Division   (Japan)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

BREEZHALER ; Chronic obstructive pulmonary disease; Dry powder inhaler; ELLIPTA

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CAPSULE DRY POWDER INHALER; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DELIVERY SYSTEM; DRY POWDER INHALER; ERROR; FEMALE; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OPEN STUDY; PATIENT PREFERENCE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; CHECKLIST; EQUIPMENT DESIGN; INHALATIONAL DRUG ADMINISTRATION; JAPAN; ODDS RATIO; STATISTICAL MODEL; TASK PERFORMANCE; VERY ELDERLY;

ADMINISTRATION, INHALATION; ADULT; AGED; AGED, 80 AND OVER; CHECKLIST; CROSS-OVER STUDIES; DRY POWDER INHALERS; EQUIPMENT DESIGN; FEMALE; HUMANS; JAPAN; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PATIENT PREFERENCE; SURVEYS AND QUESTIONNAIRES; TASK PERFORMANCE AND ANALYSIS;

EID: 84916942283     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S72762     Document Type: Article

References (14)

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of COPD – updated January 2014. Available from: http://www.goldcopd.org. Accessed July 30, 2014.
2. Lavorini F, Magnan A, Dubus JC, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008;102:593–604.
3. Raherison C, Girodet PO. Epidemiology of COPD. Eur Respir Rev. 2009;18:213–221.
4. Vincken W, Dekhuijzen R, Barnes P; ADMIT group. The ADMIT series – issues in inhalation therapy. 4 How to choose inhaler devices for the treatment of COPD. Prim Care Respir J. 2010;19:10–20.
5. Jarvis S, Ind PW, Shiner RJ. Inhaled therapy in elderly COPD patients; time for re-evaluation? Age Ageing. 2007;36:213–218.
6. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J. 2002;19: 246–251.
7. Chrystyn H, Small M, Milligan G, Higgins V, Gil EG, Estruch J. Impact of patients’ satisfaction with their inhalers on treatment compliance and health status in COPD. Respir Med. 2014;108:358–365.
8. Shikiar R, Rentz AM. Satisfaction with medication: an overview of conceptual, methodologic, and regulatory issues. Value Health. 2004;7: 204–215.
9. Komase Y, Akimoto A, Kobayashi A. [Evaluation of operability of a novel inhaler – A study of handling errors in inhalation therapy-naive subjects]. Allergy Meneki. 2014;21:146–160. Japanese.
10. Breezhaler patient information leaflet. Available from: http://www.medicines.org.uk/emc/medicine/23261/PIL/Onbrez+Breezhaler+150+and+300+microgram+inhalation+powder,+hard+capsules. Accessed September 17, 2014.
11. Chapman KR, Fogarty CM, Peckitt C, et al. Delivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPD. Int J Chron Obstruct Pulmon Dis. 2011;6:353–363.
12. Nimmo CJ, Chen DN, Martinusen SM, Ustad TL, Ostrow DN. Assessment of patient acceptance and inhalation technique of a pressurized aerosol inhaler and two breath-actuated devices. Ann Pharmacother. 1993;27:922–927.
13. Svedsater H, Dale P, Garrill K, Walker R, Woepse MW. Qualitative assessment of attributes and ease of use of the Ellipta™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm Med. 2013;13:72.
14. Svedsater H, Jacques L, Goldfrad C, Bleecker ER. Ease of use of the Ellipta dry powder inhaler: data from three randomised controlled trials in patients with asthma. NPJ Prim Care Respir Med. 2014;24:14019.